How has your use of SLT changed given the 6-year results of the LiGHT trial?  

I offer primary SLT to almost all of my treatment-naive patients with OHTN or POAG, and most patients with mild-moderate disease who have never received SLT. I counsel patients that with primary SLT, they are less likely to show disease progression at 6 years and less likely to require incisional gl...

I agree with Dr. @Hock. I also offer SLT to all my OAG/OHTN patients as a treatment option. The LiGHT Trial reaffirmed the clinical benefits of sustained 24/7 IOP management. I will combine SLT treatment with Durysta when necessary to add to my “dropless” management of glaucoma. Most gla...

I agree with Dr. @Hock and Dr. @Gallousis. I offer all new open-angle glaucoma patients SLT as an alternative to drops, and I bring up the LiGHT trial each time. An important finding in the 6-year paper is that 45% patients who were drop-free at 6 years required more than one SLT treatment to get th...